Burke J T, Wargin W A, Sherertz R J, Sanders K L, Blum M R, Sarubbi F A
J Pharmacokinet Biopharm. 1982 Dec;10(6):601-14. doi: 10.1007/BF01062543.
The pharmacokinetics of chloramphenicol (CAP) and total chloramphenicol succinate (CAPS) were studied in eight hospitalized adult patients with normal renal and hepatic function receiving intravenous chloramphenicol sodium succinate therapy. The steady-state peak concentrations of CAP (8.4-26.0 micrograms/ml) occurred at an average of 18.0 min (range 5.4-40.2) after cessation of the chloramphenicol sodium succinate infusion. Unhydrolyzed CAPS prodrug, representing 26.0 +/- 7.0% of the dose, was recovered unchanged in the urine indicating that the bioavailability of CAP from a dose of intravenous chloramphenicol succinate is not complete. A pharmacokinetic model was developed for simultaneous fitting of CAP and CAPS plasma concentration data. Pharmacokinetic parameters determined by simultaneous fitting were: V, 0.81 +/- 0.18 liters/kg; t1/2, 3.20 +/- 1.02 hr; CLB, 3.21 +/- 1.27 ml/min/kg for chloramphenicol; and V, 0.38 +/- 0.13 liters/kg; t1/2, 0.57 +/- 0.12 hr; CLB, 7.72 +/- 1.87 ml/min/kg for total chloramphenicol succinate.
在八名肾功能和肝功能正常的住院成年患者中,研究了接受静脉注射琥珀氯霉素钠治疗时氯霉素(CAP)和琥珀氯霉素总量(CAPS)的药代动力学。在停止琥珀氯霉素钠输注后,CAP的稳态峰浓度(8.4 - 26.0微克/毫升)平均出现在18.0分钟(范围5.4 - 40.2分钟)。未水解的CAPS前药占给药剂量的26.0 +/- 7.0%,在尿液中未发生变化,这表明静脉注射琥珀氯霉素剂量中CAP的生物利用度不完全。建立了一个药代动力学模型,用于同时拟合CAP和CAPS的血浆浓度数据。通过同时拟合确定的药代动力学参数为:氯霉素的V,0.81 +/- 0.18升/千克;t1/2,3.20 +/- 1.02小时;CLB,3.21 +/- 1.27毫升/分钟/千克;琥珀氯霉素总量的V,0.38 +/- 0.13升/千克;t1/2,0.57 +/- 0.12小时;CLB,7.72 +/- 1.87毫升/分钟/千克。